Abstract:The goal of this research was to find a way to enhance the pharmacological activity of Capecitabine (CAP) and Thymoquinone (TQ) while also decreasing the likelihood of drug resistance by studying the synergistic activity of TQ, formulating the functionalized polymeric nanoparticles (PNPs) as carriers for effectively targeting the colon to manage colorectal cancer (CRC). CAP and TQ-loaded galactosylated PLGA nanoparticles coated with Eudragit-S-100 were created and optimized to target the colon's pH for drug release after oral delivery using Box-Behnken design. The standard study revealed that they had a high stability of normal pH, a tiny size of spherical shape droplets, and a unique zeta potential that was non-toxic and promoted faster cell migration. Cancer cells treated with PNPs that had a protective effect on intracellular reactive oxygen species (ROS), oxidative stress, and mitochondrial membrane potential had their apoptotic morphology altered to promote cell survival. Moreover, the investigation of pharmacodynamics on male Wistar rats unveiled a notable reduction in the number of tumors, aberrant crypt foci, accompanied by a discernible amelioration in dysplastic characteristics and enhancement in various blood parameters, and its toxic effects were mitigated proving Galactosylation to be a reliable method which has shown to be useful in targeting CRC through galectin-mediated endocytosis. When compared to free CAP, the targeted approach increases cytotoxicity and cell death. The data demonstrated that the targeted method maximized the efficacy of CAP in regulating tumor development, enhancing apoptosis and decreasing drug resistance. This demonstrated that the engineered PNP showed encouraging anticancer activity with less toxicity and may be employed as an efficient carrier against cancer. Docking research stated that TQ had the maximum binding affinity to Mitogen-activated protein kinase kinase molecule which is inextricably linked to colon cancer (binding energy −6.07 kcal/mol). This is the first work to our knowledge to demonstrate that eudragit S-100 coated CAP and TQ-loaded Galactosylated PLGANP can induce apoptosis, which could be used to kill off cancer cells. Graphical abstract Download : Download high-res image (293KB) Download : Download full-size image

Acid-triggered rattan ball-like β-glucan carrier embedding doxorubicin to synergistically alleviate precancerous lesions of gastric cancer via p53 and PI3K pathways

Synergistic Effects of Antitumor Efficacy Via Mixed Nano-Size Micelles of Multifunctional Bletilla Striata Polysaccharide-Based Copolymer and D-α-tocopheryl Polyethylene Glycol Succinate.

Synergism of Rmv-Hu191 with Cisplatin to Treat Gastric Cancer by Acid Sphingomyelinase-Mediated Apoptosis Requiring Integrity of Lipid Raft Microdomains

Bioinspired ginsenoside Rg3 PLGA nanoparticles coated with tumor-derived microvesicles to improve chemotherapy efficacy and alleviating toxicity

Stepwise dual pH and redox-responsive cross-linked polypeptide nanoparticles for enhanced cellular uptake and effective cancer therapy.

In Vitro and in Vivo Evaluation of Stimuli-Responsive Vesicle from PEGylated Hyperbranched PAMAM-doxorubicin Conjugate for Gastric Cancer Therapy.

Surface PEGylated Cancer Cell Membrane-Coated Nanoparticles for Codelivery of Curcumin and Doxorubicin for the Treatment of Multidrug Resistant Esophageal Carcinoma

Glutathione-Responsive Plga Nanocomplex For Dual Delivery Of Doxorubicin And Curcumin To Overcome Tumor Multidrug Resistance

CD44/Folate Dual Targeting Receptor Reductive Response PLGA-Based Micelles for Cancer Therapy

Fabrication of Poly Dopamine@poly (Lactic Acid-Co-Glycolic Acid) Nanohybrids for Cancer Therapy via a Triple Collaboration Strategy

Highly Biocompatible Functionalized Layer‐by‐Layer Ginger Lipid Nano Vectors Targeting P‐Selectin for Delivery of Doxorubicin to Treat Colon Cancer

Ph-Responsive Polymeric Micelles Based on Poly(2-Ethyl-2-oxazoline)-poly(d,l-lactide) for Tumor-Targeting and Controlled Delivery of Doxorubicin and P-glycoprotein Inhibitor

Pluronic-based functional polymeric mixed micelles for co-delivery of doxorubicin and paclitaxel to multidrug resistant tumor.

RGD Peptides-Conjugated Pluronic Triblock Copolymers Encapsulated with AP-2α Expression Plasmid for Targeting Gastric Cancer Therapy in Vitro and in Vivo

Hybrid PEGylated chitosan/PLGA nanoparticles designed as pH-responsive vehicles to promote intracellular drug delivery and cancer chemotherapy

Stromal Barrier-Dismantled Nanodrill-Like and Cancer Cell-Targeted Ph-Responsive Polymeric Micelles for Further Enhancing the Anticancer Efficacy of Doxorubicin

Glycyrrhetinic acid remodels the tumor microenvironment and synergizes with doxorubicin for breast cancer treatment in a murine model

Co-delivery of doxorubicin and curcumin via cRGD-peptide modified PEG-PLA self-assembly nanomicelles for lung cancer therapy

Poly (l-γ-glutamylglutamine) Polymer Enhances Doxorubicin Accumulation in Multidrug Resistant Breast Cancer Cells.

Glycyrrhetinic acid-cyclodextrin grafted pullulan nanoparticles loaded doxorubicin as a liver targeted delivery carrier

An innovative synergistic combination using eudragit-coated galactosylated PLGA-pluronic nanoparticles for addressing colorectal cancer